Business
Hyperfine, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results
GUILFORD, Conn., March 17, 2025 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced fourth quarter and full year 2024 financial results and provided a business update. “I am pleased with the many milestones we achieved in the fourth quarter of 2024. These set the stage well for us to execute on
About this update from Hyperfine, Inc.
[{"type":"image","alt":"Hyperfine, Inc.","displaySize":"","headline":null,"caption":"Hyperfine, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":35,"url":"https://media.zenfs.com/en/globenewswire.com/2b1f9ab562f8c1b1fa45bccf3d1c5fcd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/lv92NC_R8ciUU.bll_Q6eQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQ5O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/2b1f9ab562f8c1b1fa45bccf3d1c5fcd","width":300,"height":35}},"lazy":false},{"type":"text","content":"GUILFORD, Conn., March 17, 2025 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced fourth quarter and full year 2024 financial results and provided a business update.","length":371,"tagName":"p"},{"type":"text","content":"“I am pleased with the many milestones we achieved in the fourth quarter of 2024. These set the stage well for us to execute on our expansion plan, drive accelerated growth across multiple sites of care globally and meaningfully reduce cash burn in 2025,” said Maria Sainz, Chief Executive Officer and President of Hyperfine, Inc. “This year, we are planning two AI-powered software launches, with image quality approaching that of high-field. 2025 will be a tale of two halves, starting the year with commercial activity mainly in our U.S. critical care business and by the end of the year, we expect to be actively selling into several sites of care in the hospital setting, neurology offices and into more international markets.”","length":732,"tagName":"p"},{"type":"text","content":"Recent Achievements and Business Highlights","length":43,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Strengthened our financial profile by completing a reorganization to lower our operating costs and raising $6.0 million through a registered direct offering to extend our cash runway, which is now expected to enable us to conduct our planned operations until the end of 2026.","length":275,"tagName":"p"}]},{"val":[{"type":"text","content":"Accreditation guidelines published by the Intersocietal Accreditation Commission (IAC) including ultra-low-field MRI technology and allowing accredited facilities t...